<DOC>
	<DOCNO>NCT01076374</DOCNO>
	<brief_summary>The primary purpose study assess long term reliability Medtronic Adapta®/Sensia™/Versa™ platform device . This study require FDA condition approval nEw3 device . Patients follow 5 year implant . This study utilize data collect System Longevity Study ( SLS ) .</brief_summary>
	<brief_title>nEw3 Post-approval Study</brief_title>
	<detailed_description>The rate device malfunction determine comparison historical control do .</detailed_description>
	<mesh_term>Bradycardia</mesh_term>
	<criteria>Subjects appropriate legal guardian provide write informed consent and/or authorization access use health information , require institution 's IRB/MEC/REB . AND one following must also apply : Subjects indicate implant within six month postimplant Medtronic marketreleased lead connect Medtronic Adapta® , Sensia™ , Versa™ IPG . The Medtronic lead must use pacing , sense defibrillation application . Subjects participate qualify study ( IDE ) Medtronic cardiac therapy product : 1 ) Medtronic Adapta® , Sensia™ , Versa™ IPG 2 ) product marketreleased 3 ) complete implant followup data , include productrelated adverse event available 4 ) subject appropriate legal guardian authorize release subject study data SLS Subjects implant Medtronic Adapta® , Sensia™ , Versa™ IPG Medtronic CapSure Epi Leads ( model 4965 4968 ) minimum three preselected site retrospectively collect data post approval requirement . Subjects , inaccessible followup SLS center Subjects exclusion criterion require local law ( EMEA ) Subjects receive implant Medtronic device nonparticipating center implant data current status confirm within 30 day implant Subjects implant Medtronic device whose predetermined enrollment limit specific product exceed</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>pacemaker</keyword>
</DOC>